Health

Add as a preferred source on Google

Adcendo Reports 30% Response Rate in Early Sarcoma Drug Trial

Eight of 27 response-evaluable patients had partial responses. Median follow-up was 3.4 months, and the study is ongoing.

Updated 2 min read
A microscope and specimen trays sit in a research laboratory in Barcelona, Spain. (AI-generated image / EconoTimes)
A microscope and specimen trays sit in a research laboratory in Barcelona, Spain. (AI-generated image / EconoTimes)

Adcendo ApS reported partial responses in eight of 27 response-evaluable patients with advanced soft tissue sarcoma who received its investigational drug ADCE-D01 every two weeks, in early results from an ongoing trial.

The company said the objective response rate was 30% and the disease control rate was 85%, or 23 of 27 patients. Five responses were confirmed and three were unconfirmed at the data cutoff. All eight were ongoing at that point. Median follow-up was 3.4 months, and median duration of response had not been reached.

The response-evaluable patients represented 12 sarcoma subtypes, Adcendo said, and 22 remained on treatment at the cutoff. A separate safety analysis covered 47 adults with advanced soft tissue sarcoma across 17 subtypes who had previously received systemic therapies. Adcendo described safety and tolerability on the every-two-week schedule as favorable, citing few dose reductions and no discontinuations because of side effects.

ADCE-D01 is an investigational antibody-drug conjugate that targets uPARAP. Adcendo says it combines an antibody that binds the protein with a deruxtecan-derived topoisomerase I inhibitor payload.

The ongoing ADCElerate1 trial is a first-in-human Phase 1/2 study with dose-escalation, dose-confirmation and expansion phases. Early objectives include assessing safety and tolerability, and the study is recruiting.

Principal investigator Patrick Schöffski presented the findings at the 38th EORTC-NCI-AACR Symposium in Barcelona on Nov. 19. The early results do not establish how long responses will last; median duration of response has not yet been reached.

Related articles

View all